These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8950801)

  • 21. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens.
    Morelli VM; de Visser MC; van Tilburg NH; Vos HL; Eikenboom JC; Rosendaal FR; Bertina RM
    Thromb Haemost; 2007 Apr; 97(4):534-41. PubMed ID: 17393014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
    Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
    Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells--the importance of consensus on the use of correction factors for haemoconcentration.
    Wieczorek I; Ludlam CA; MacGregor I
    Thromb Haemost; 1993 Jan; 69(1):91, 93. PubMed ID: 8446947
    [No Abstract]   [Full Text] [Related]  

  • 25. [Molecular structure and function of von Willebrand factor in blood coagulation and fibrinolysis].
    Fujimura Y
    Nihon Rinsho; 1989 Apr; 47(4):836-43. PubMed ID: 2501538
    [No Abstract]   [Full Text] [Related]  

  • 26. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle.
    Miller CH; Dilley AB; Drews C; Richardson L; Evatt B
    Thromb Haemost; 2002 Jun; 87(6):1082-3. PubMed ID: 12083494
    [No Abstract]   [Full Text] [Related]  

  • 28. Von Willebrand factor does not vary during normal menstrual cycle.
    Onundarson PT; Gudmundsdottir BR; Arnfinnsdottir AV; Kjeld M; Olafsson O
    Thromb Haemost; 2001 Jan; 85(1):183-4. PubMed ID: 11204575
    [No Abstract]   [Full Text] [Related]  

  • 29. Interaction of factor VIII and von Willebrand factor and the identification of type 2N von Willebrand disease.
    Favaloro EJ
    Thromb Res; 2011 Jan; 127(1):2-3. PubMed ID: 21084106
    [No Abstract]   [Full Text] [Related]  

  • 30. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I; Farrugia A; Tran E; Anastasius V; Charnock A
    Biologicals; 1998 Jun; 26(2):155-66. PubMed ID: 9811523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
    Berntorp E
    Haematologica; 2003 Jun; 88(6):EREP03. PubMed ID: 12826529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
    Favaloro EJ
    Semin Thromb Hemost; 2006 Sep; 32(6):566-76. PubMed ID: 16977567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
    De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.
    Rastegar-Lari G; Ajzenberg N; Ribba AS; Vereycken-Holler V; Legendre P; Villoutreix B; Meyer D; Baruch D
    Thromb Haemost; 2001 Dec; 86(6):1459-65. PubMed ID: 11776314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factor VIII structure and proteolytic processing.
    Eaton DL; Vehar GA
    Prog Hemost Thromb; 1986; 8():47-70. PubMed ID: 3104988
    [No Abstract]   [Full Text] [Related]  

  • 38. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions.
    Rivera J; Escolar G; Casamiquela R; Bravo MI; Jorquera JI; Castillo R; Ordinas A; Vicente V
    Haematologica; 1999 Jan; 84(1):5-11. PubMed ID: 10091386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure and function of the factor VIII gene and protein.
    Thompson AR
    Semin Thromb Hemost; 2003 Feb; 29(1):11-22. PubMed ID: 12640560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.